Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 33 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation ApproachCompletedNCT03702179Phase 2Results posted
• A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk MelanomaActive, not recruitingNCT03698019Phase 2Results posted
• Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic CancerCompletedNCT03697564Phase 2Results posted
• Pembrolizumab in Treating Patients With Stage IB-IV Mycosis FungoidesCompletedNCT03695471Phase 2Results posted
• BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver CancerTerminatedNCT03695250Phase 1/2Results posted
• The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)CompletedNCT03694262Phase 2Results posted
• Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal TumorsTerminatedNCT03693846Phase 2Results posted
• GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsCompletedNCT03693612Phase 1/2Results posted
• A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung CancerCompletedNCT03693300Phase 2Results posted
• Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous LeukoplakiaCompletedNCT03692325Phase 2Results posted
• Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03691714Phase 2Results posted
• REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent GliomaTerminatedNCT03690869Phase 1/2Results posted
• Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLCCompletedNCT03689855Phase 2Results posted
• Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)CompletedNCT03689699Phase 1/2Results posted
• Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular LymphomaTerminatedNCT03685344Phase 1Results posted
• Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular CarcinomaCompletedNCT03682276Phase 1/2Results posted
• Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell CarcinomaCompletedNCT03680521Phase 2Results posted
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)CompletedNCT03679767Phase 2Results posted
• Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Phase 3Results posted
• A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)CompletedNCT03668119Phase 2Results posted
• A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT03666143Phase 1Results posted
• Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)CompletedNCT03664024Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung CancerCompletedNCT03663205Phase 3Results posted
• Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03663166Phase 1/2Results posted
• An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) CancersCompletedNCT03662659Phase 2Results posted
• Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung CancerTerminatedNCT03662074Phase 2Results posted
• Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent GlioblastomaCompletedNCT03661723Phase 2Results posted
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingNCT03660826Phase 2Results posted
• Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal CancerActive, not recruitingNCT03657641Phase 1/2Results posted
• A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)CompletedNCT03656718Phase 1/2Results posted
• Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based ChemotherapyTerminatedNCT03655444Phase 1/2Results posted
• Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedNCT03654833Phase 2Results posted
• Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03650764Phase 1/2Results posted
• Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung CancerCompletedNCT03647488Phase 2Results posted
• Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCCTerminatedNCT03646461Phase 2Results posted
• Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal CancerCompletedNCT03642067Phase 2Results posted
• Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast CancerActive, not recruitingNCT03639948Phase 2Results posted
• Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyCompletedNCT03639935Phase 2Results posted
• CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and TremelimumabCompletedNCT03638141Phase 2Results posted
• Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced MalignanciesTerminatedNCT03637764Phase 1/2Results posted
• Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate CancerActive, not recruitingNCT03637543Phase 2Results posted
• A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid TumorsTerminatedNCT03637491Phase 1/2Results posted
• A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102CompletedNCT03636477Phase 1Results posted
• A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaCompletedNCT03635983Phase 3Results posted
• Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)CompletedNCT03635567Phase 3Results posted
• Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)TerminatedNCT03634800Phase 2Results posted
• Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung StudyCompletedNCT03634241Phase 2Results posted
• A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast CancerTerminatedNCT03632941Phase 2Results posted
• Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial ColectomyTerminatedNCT03631641Phase 2Results posted
• Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)CompletedNCT03631407Phase 2Results posted
• Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's MacroglobulinaemiaCompletedNCT03630042Phase 2Results posted
• Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLCCompletedNCT03629925Phase 3Results posted
• Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCCCompletedNCT03625323Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System MetastasesCompletedNCT03625141Phase 2Results posted
• Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder CancerCompletedNCT03617913Phase 2Results posted
• Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Phase 3Results posted
• MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.CompletedNCT03611556Phase 1/2Results posted
• Lenvatinib and Pembrolizumab Simultaneous Combination StudyCompletedNCT03609359Phase 2Results posted
• Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLCCompletedNCT03607539Phase 3Results posted
• A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerActive, not recruitingNCT03602859Phase 3Results posted
• Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian CancerCompletedNCT03602586Phase 2Results posted
• Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerActive, not recruitingNCT03600701Phase 2Results posted
• pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate CancerActive, not recruitingNCT03600350Phase 2Results posted
• A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)CompletedNCT03599713Phase 2Results posted
• Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic CancerTerminatedNCT03599362Phase 2Results posted
• Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasActive, not recruitingNCT03598998Phase 1/2Results posted
• A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)CompletedNCT03597295Phase 2Results posted
• A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural EffusionTerminatedNCT03597009Phase 1/2Results posted
• A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)CompletedNCT03595657Phase 2Results posted
• A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Active, not recruitingNCT03595124Phase 2Results posted
• A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung CancerCompletedNCT03594747Phase 3Results posted
• Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell LymphomasCompletedNCT03586999Phase 1/2Results posted
• Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic TumorsCompletedNCT03583086Phase 1/2Results posted
• Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or ProstateActive, not recruitingNCT03582475Phase 1Results posted
• The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Phase 3Results posted
• Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerCompletedNCT03581487Phase 1/2Results posted
• A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung CancerCompletedNCT03575793Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian CancerCompletedNCT03574779Phase 2Results posted
• Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLCCompletedNCT03573947Phase 2Results posted
• Rucaparib and Nivolumab in Patients With Prostate or Endometrial CancerTerminatedNCT03572478Phase 1/2Results posted
• Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsCompletedNCT03570619Phase 2Results posted
• IBI308 in Subjects With Advanced/Metastatic Solid MalignanciesCompletedNCT03568539Phase 1Results posted
• Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced CancersCompletedNCT03568058Phase 1Results posted
• Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid TumorsTerminatedNCT03565991Phase 2Results posted
• A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT03563716Phase 2Results posted
• Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03559049Phase 1/2Results posted
• SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.CompletedNCT03558191Phase 2Results posted
• Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum ChemotherapyCompletedNCT03558139Phase 1Results posted
• Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder SparingCompletedNCT03558087Phase 2Results posted
• Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial CancerCompletedNCT03557918Phase 2Results posted
• Nivolumab for Recurrent or Progressive IDH Mutant GliomasCompletedNCT03557359Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)TerminatedNCT03555149Phase 1/2Results posted
• COMbination of Bipolar Androgen Therapy and NivolumabCompletedNCT03554317Phase 2Results posted
• Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III MelanomaCompletedNCT03554083Phase 2Results posted
• Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)Active, not recruitingNCT03553836Phase 3Results posted
• Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell CarcinomaTerminatedNCT03552380Phase 2Results posted
• Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial CarcinomaCompletedNCT03534804Phase 2Results posted
• Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder CancerCompletedNCT03532451Phase 1Results posted
• Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent GliomasCompletedNCT03532295Phase 2Results posted
• MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal CancerCompletedNCT03531632Phase 1/2Results posted

← Immune Checkpoint Inhibitors overview